China abstracts （结肠直肠癌）ppt课件.pptVIP

BOA Colorectal Cancer Abstracts 2010;Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer. Results of the translational study on the PETACC 3 trial ;Rationale;Objectives;Stratification: Stage II vs. III Center;PETACC-3: DFS Not Significantly Improved With FOLFIRI in Stage III;PETACC3 trial: Patient Distribution;Relapsing Patients Characteristics;Univariate Analysis for SARin the marker set (N=392);Multivariate Analysis for SARin the marker set (N=392);SAR according to BRAF mutation status;Conclusions;12.3% of patients presented with recurrent CRC.*2002 data.;(1) IMPACT Investigators, 1995; (2) Wolmark et al., 1993; (3) QUASAR Group, 2000; (4) André et al., 2003. ;MOSAIC: Study Design;Disease-Free Survival: Stage II/III Colon Cancer;Overall Survival: Stage II/III;3-year DFS (Stage III):cross-trial comparison;FOLFOX as standard treatment arm;NSABP C-08 Schema; Events 3yDFS mFF6+B 291 77.4 mFF6 312 75.5;NSABP C-08 HR;Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected K-ras wild type Stage 3 Colon Cancer Cooperative Group Trial N0147(NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG);Potential Added Benefit of Targeted Therapy;Initial 2-arm Design for N0147;Role of K-ras Analysis;Final Design for N0147 – June 2008;Goals for N0147;Eligibility for N0147;Eligibility for N0147;Final Study Population;Patient Characteristics;Tumor Characteristic;Outcomes for K-ras WT Patients;Disease-Free Survival (N=1847);Disease-Free SurvivalAge70 (N=1589);Disease-Free SurvivalAge70 (N=258);Forest Plot for DFS;Overall Survival (N=1847);Toxicity – Grade 3-4;Reasons for Discontinuation;Conclusions;Conclusions;Adjuvant mFOLFOX6 +/- cetuximab in patients with K-ras mutant resected stage III colon cancer;Treatment Assignment,by K-ras Status;DFS: FOLFOX +/- Cmab by K-ras status ;DFS: FOLFOX +/- Cmab by K-ras status ;;Duration of Therapy;Was adverse